Research programme: 5-lipoxygenase activating protein inhibitors - Panmira Pharmaceuticals

Drug Profile

Research programme: 5-lipoxygenase activating protein inhibitors - Panmira Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Panmira Pharmaceuticals
  • Class
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Eye-Disorders; Skin disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-disorders in USA
  • 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top